Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

PI3K pathway inhibitors approach junction

Nature Reviews Drug Discovery volume 10, pages 563–564 (2011)Cite this article

Subjects

The PI3K–AKT–mTOR pathway has long been an attractive oncology target. But with top-line results from the most advanced AKT inhibitor due soon, many questions remain over which targets to hit and how to combine agents.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: A simplified overview of the PI3K–AKT–mTOR pathway.
Authors
  1. David Holmes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holmes, D. PI3K pathway inhibitors approach junction. Nat Rev Drug Discov 10, 563–564 (2011). https://doi.org/10.1038/nrd3527

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3527

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer